Vanguard Capital Management
CSTL icon

Vanguard Capital Management’s Castle Biosciences CSTL Stock Holding History

Vanguard Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.3M Buy
1,226,497
+48,975
+4% +$1.09M ﹤0.01% 2235
2026
Q1 		$28.9M Buy
+1,177,522
New +$38.6M ﹤0.01% 2150

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $112B AUM 36.28% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

Vanguard Capital Management's CSTL Position: Q2 2026 in Review

Vanguard Capital Management increased its Castle Biosciences (CSTL) stake by 4.2% in Q2 2026, buying an estimated $1.09M and bringing the position to 1,226,497 shares worth $29.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2235.

Vanguard Capital Management first reported a position in CSTL in Q1 2026 and has held it in 2 quarters since. 176 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Vanguard Capital Management held 1,226,497 shares of Castle Biosciences worth $29.3M as of Q2 2026.
  • Vanguard Capital Management bought 48,975 Castle Biosciences shares in Q2 2026, an estimated $1.09M.
  • Castle Biosciences made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2235 holding.
  • Vanguard Capital Management first reported a position in Castle Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 176 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.